Project summary:

Patients with advanced cancers can today be treated in Molecular Tumor Boards (MTBs) through
genetic characterization and, where possible, tailored therapies. Although MTBs have been established at all major cancer centers, cross-site harmonization and the systematic integration of genetic and clinical data are still lacking. The Molecular Tumor Board Alliance (MTBA) within the German Cancer Consortium (DKTK) addresses these gaps by developing binding standards for patient inclusion, genetic evaluation, visualization, therapy recommendations, and follow-up, in close cooperation with existing initiatives. By using harmonized and standardized datasets and providing analysis and visualization tools, MTBA makes insights accessible for both research and clinical practice.